Appropriate use criteria for amyloid PET imaging cannot replace guidelines: on behalf of the European Association of Nuclear Medicine(433 views visite) Booij J, Arbizu J, Darcourt J, Hesse S, Nobili F, Payoux P, Pappata S, Tatsch K, Walker Z, Pagani M
Keywords Parole chiave: Amyloid Beta-Peptides Metabolism, Brain Metabolism Radionuclide Imaging, Humans, Positron-Emission Tomography Methods, Amyloid Beta Protein, Florbetaben, Florbetapir F 18, Flutemetamol F 18, Pittsburgh Compound B, Alzheimer Disease, Brain Perfusion, Cerebrospinal Fluid Analysis, Clinical Practice, Cost Effectiveness Analysis, Dementia, Diffuse Lewy Body Disease, Disease Course, Disease Severity, Dopaminergic System, Early Diagnosis, Food And Drug Administration, Health Care Personnel, Medical Society, Mild Cognitive Impairment, Molecular Imaging, Pathogenesis, Positron Emission Tomography, Practice Guideline, Review, Risk Benefit Analysis, Risk Factor,
Affiliations Affiliazioni: *** IBB - CNR ***
Department of Nuclear Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands Nuclear Medicine Department, Clinica Universidad de Navarra, University of Navarra, Pamplona, Spain Clinical Neurophysiology, Department of Neurosciences, Ophthalmology and Genetics, University of Genoa, Genoa, Italy INSERM, Toulouse, France Institute of Biostructure and Bioimaging, CNR, Naples, Italy Department of Mental Health Sciences Unit, University College London, London, United Kingdom Institute of Cognitive Sciences and Technologies, CNR, Rome, Italy
References Riferimenti: Johnson, K.A., Minoshima, S., Bohnen, N.I., Donohoe, K.J., Foster, N.L., Herscovitch, P., Appropriate use criteria for amyloid PET: A report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's Association (2013) J Nucl Med, 54, pp. 476-490. , 23359661 10.2967/jnumed.113.120618 1:CAS:528:DC%2BC3sXltV2ks7g%3
Klunk, W.E., Engler, H., Nordberg, A., Wang, Y., Blomqvist, G., Holt, D.P., Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B (2004) Ann Neurol, 55, pp. 306-319. , 14991808 10.1002/ana.20009 1:CAS:528:DC%2BD2cXisFKntb8%3D
Kemppainen, N.M., Aalto, S., Wilson, I.A., Någren, K., Helin, S., Brück, A., Voxel-based analysis of PET amyloid ligand [11C]PIB uptake in Alzheimer disease (2006) Neurology, 67, pp. 1575-1580. , 16971697 10.1212/01.wnl.0000240117.55680.0a 1:STN:280: DC%2BD28nmslagsQ%3D%3D
Edison, P., Archer, H.A., Hinz, R., Hammers, A., Pavese, N., Tai, Y.F., Amyloid, hypometabolism, and cognition in Alzheimer disease: An [11C]PIB and [18F]FDG PET study (2007) Neurology, 68, pp. 501-508. , 17065593 10.1212/01.wnl.0000244749.20056.d4 1:STN:280: DC%2BD2s%2FpsFymsA%3D%3D
Edison, P., Rowe, C.C., Rinne, J.O., Ng, S., Ahmed, I., Kemppainen, N., Amyloid load in Parkinson's disease dementia and Lewy body dementia measured with [11C]PIB positron emission tomography (2008) J Neurol Neurosurg Psychiatry, 79, pp. 1331-1338. , 18653550 10.1136/jnnp.2007.127878 1:STN:280:DC%2BD1cjktFSgsg%3D%3D
Gomperts, S.N., Rentz, D.M., Moran, E., Becker, J.A., Locascio, J.J., Klunk, W.E., Imaging amyloid deposition in Lewy body diseases (2008) Neurology, 71, pp. 903-910. , 18794492 10.1212/01.wnl.0000326146.60732.d6 1:STN:280: DC%2BD1cngs1amtw%3D%3D
Chételat, G., Villemagne, V.L., Bourgeat, P., Pike, K.E., Jones, G., Ames, D., Relationship between atrophy and beta-amyloid deposition in Alzheimer disease (2010) Ann Neurol, 67, pp. 317-324. , 20373343
Santillo, A.F., Gambini, J.P., Lannfelt, L., Långström, B., Ulla-Marja, L., Kilander, L., In vivo imaging of astrocytosis in Alzheimer's disease: An 11C-L-deuteriodeprenyl and PIB PET study (2011) Eur J Nucl Med Mol Imaging, 38, pp. 2202-2208. , 21853308 10.1007/s00259-011-1895-9
Nordberg, A., Carter, S.F., Rinne, J., Drzezga, A., Brooks, D.J., Vandenberghe, R., A European multicentre PET study of fibrillar amyloid in Alzheimer's disease (2013) Eur J Nucl Med Mol Imaging, 40, pp. 104-114. , 22961445 10.1007/s00259-012-2237-2 1:CAS:528:DC%2BC38XhslyjtrvP
Tolboom, N., Yaqub, M., Boellaard, R., Luurtsema, G., Windhorst, A.D., Scheltens, P., Test-retest variability of quantitative [11C]PIB studies in Alzheimer's disease (2009) Eur J Nucl Med Mol Imaging, 36, pp. 1629-1638. , 19384547 10.1007/s00259-009-1129-6
Engler, H., Santillo, A.F., Wang, S.X., Lindau, M., Savitcheva, I., Nordberg, A., In vivo amyloid imaging with PET in frontotemporal dementia (2008) Eur J Nucl Med Mol Imaging, 35, pp. 100-106. , 17846768 10.1007/s00259-007-0523-1
Bacskai, B.J., Frosch, M.P., Freeman, S.H., Raymond, S.B., Augustinack, J.C., Johnson, K.A., Molecular imaging with Pittsburgh Compound B confirmed at autopsy: A case report (2007) Arch Neurol, 64, pp. 431-434. , 17353389 10.1001/archneur.64.3.431
Ikonomovic, M.D., Klunk, W.E., Abrahamson, E.E., Mathis, C.A., Price, J.C., Tsopelas, N.D., Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease (2008) Brain, 131, pp. 1630-1645. , 18339640 10.1093/brain/awn016
Ikonomovic, M.D., Abrahamson, E.E., Price, J.C., Hamilton, R.L., Mathis, C.A., Paljug, W.R., Early AD pathology in a [C-11]PiB-negative case: A PiB-amyloid imaging, biochemical, and immunohistochemical study (2012) Acta Neuropathol., 123, pp. 433-447. , 22271153 10.1007/s00401-012-0943-2 1:CAS:528:DC%2BC38Xisl2ktbk%3D
Rowe, C.C., Ackerman, U., Browne, W., Mulligan, R., Pike, K.L., O'Keefe, G., Imaging of amyloid ß in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: Proof of mechanism (2008) Lancet Neurol, 7, pp. 129-135. , 18191617 10.1016/S1474-4422(08)70001-2 1:CAS:528:DC%2BD1cXis1WmsLw%3D
Koole, M., Lewis, D.M., Buckley, C., Nelissen, N., Vandenbulcke, M., Brooks, D.J., Whole-body biodistribution and radiation dosimetry of 18F-GE067: A radioligand for in vivo brain amyloid imaging (2009) J Nucl Med, 50, pp. 818-822. , 19372469 10.2967/jnumed.108.060756 1:CAS:528:DC%2BD1MXmtV2hsrk%3D
Wong, D.F., Rosenberg, P.B., Zhou, Y., Kumar, A., Raymont, V., Ravert, H.T., In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18F-AV-45 (florbetapir F 18) (2010) J Nucl Med, 51, pp. 913-920. , 20501908 10.2967/jnumed.109.069088 1:CAS:528:DC%2BC3cXosl2ksb4%3D
Clark, C.M., Schneider, J.A., Bedell, B.J., Beach, T.G., Bilker, W.B., Mintun, M.A., Use of florbetapir-PET for imaging beta-amyloid pathology (2011) JAMA, 305, pp. 275-283. , 21245183 10.1001/jama.2010.2008 1:CAS:528:DC%2BC3MXhtVGrurw%3D
Barthel, H., Gertz, H.J., Dresel, S., Peters, O., Bartenstein, P., Buerger, K., Cerebral amyloid-ß PET with florbetaben (18F) in patients with Alzheimer's disease and healthy controls: A multicentre phase 2 diagnostic study (2011) Lancet Neurol, 10, pp. 424-435. , 21481640 10.1016/S1474-4422(11)70077-1 1:CAS:528:DC%2BC3MXlt1Sls7c%3D
Cselényi, Z., Jönhagen, M.E., Forsberg, A., Halldin, C., Julin, P., Schou, M., Clinical validation of 18F-AZD4694, an amyloid-ß-specific PET radioligand (2012) J Nucl Med, 53, pp. 415-424. , 22323782 10.2967/jnumed.111.094029
Clark, C.M., Pontecorvo, M.J., Beach, T.G., Bedell, B.J., Coleman, R.E., Doraiswamy, P.M., Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-ß plaques: A prospective cohort study (2012) Lancet Neurol, 11, pp. 669-678. , 22749065 10.1016/S1474-4422(12)70142-4 1:CAS:528:DC%2BC38XhtV2gtb3E
Rinne, J.O., Wong, D.F., Wolk, D.A., Leinonen, V., Arnold, S.E., Buckley, C., [18F]Flutemetamol PET imaging and cortical biopsy histopathology for fibrillar amyloid ß detection in living subjects with normal pressure hydrocephalus: Pooled analysis of four studies (2012) Acta Neuropathol, 124, pp. 833-845. , 23053137 10.1007/s00401-012-1051-z 1:CAS:528:DC%2BC38XhslKls7zI
Okello, A., Koivunen, J., Edison, P., Archer, H.A., Turkheimer, F.E., Någren, K., Conversion of amyloid positive and negative MCI to AD over 3 years: An 11C-PIB PET study (2009) Neurology, 73, pp. 754-760. , 19587325 10.1212/WNL.0b013e3181b23564 1:CAS:528:DC%2BD1MXhtVKrsbvF
Koivunen, J., Scheinin, N., Virta, J.R., Aalto, S., Vahlberg, T., Någren, K., Amyloid PET imaging in patients with mild cognitive impairment: A 2-year follow-up study (2011) Neurology, 76, pp. 1085-1090. , 21325653 10.1212/WNL.0b013e318212015e 1:STN:280:DC%2BC3M3ot1Klsg%3D%3D
Morris, J.C., Price, J.L., Pathologic correlates of nondemented aging, mild cognitive impairment, and early-stage Alzheimer's disease (2001) J Mol Neurosci, 17, pp. 101-118. , 11816784 10.1385/JMN:17:2:101 1:CAS:528:DC%2BD3MXosVKitrg%3D
Varrone, A., Asenbaum, S., Vander Borght, T., Booij, J., Nobili, F., Någren, K., EANM procedure guidelines for PET brain imaging using [18F]FDG, version 2 (2009) Eur J Nucl Med Mol Imaging, 36, pp. 2103-2110. , 19838705 10.1007/s00259-009-1264-0
Kapucu, O.L., Nobili, F., Varrone, A., Booij, J., Vander Borght, T., Någren, K., EANM procedure guideline for brain perfusion SPECT using 99mTc-labelled radiopharmaceuticals, version 2 (2009) Eur J Nucl Med Mol Imaging, 36, pp. 2093-2102. , 19838703 10.1007/s00259-009-1266-y 1:CAS:528:DC%2BD1MXhsVCisb3L
Van Laere, K., Varrone, A., Booij, J., Vander Borght, T., Nobili, F., Kapucu, O.L., EANM procedure guidelines for brain neurotransmission SPECT/PET using dopamine D2 receptor ligands, version 2 (2010) Eur J Nucl Med Mol Imaging, 37, pp. 434-442. , 19838704 10.1007/s00259-009-1265-z 1:CAS:528:DC%2BC3cXhsVyisL0%3D
Darcourt, J., Booij, J., Tatsch, K., Varrone, A., Vander Borght, T., Kapucu, O.L., EANM procedure guidelines for brain neurotransmission SPECT using 123I-labelled dopamine transporter ligands, version 2 (2010) Eur J Nucl Med Mol Imaging, 37, pp. 443-450. , 19838702 10.1007/s00259-009-1267-x 1:CAS:528:DC%2BC3cXhsVyitr0%3D
Patel, M.R., Spertus, J.A., Brindis, R.G., Hendel, R.C., Douglas, P.S., Peterson, E.D., ACCF proposed method for evaluating the appropriateness of cardiovascular imaging (2005) J Am Coll Cardiol, 46, pp. 1606-1613. , 16226195 10.1016/j.jacc.2005.08.030
Delbeke, D., Chiti, A., Christian, P., Darcourt, J., Donohoe, K., Flotats, A., SNMMI/EANM guideline for guideline development 6.0 (2012) J Nucl Med Technol, 40, pp. 283-289. , 22743147 10.2967/jnmt.112.108787
Dubois, B., Feldman, H.H., Jacova, C., Cummings, J.L., Dekosky, S.T., Barberger-Gateau, P., Revising the definition of Alzheimer's disease: A new lexicon (2010) Lancet Neurol, 9, pp. 1118-1127. , 20934914 10.1016/S1474-4422(10)70223-4
Advisory Committee Briefing Document. New Drug Application 202-008: Amyvid (Florbetapir F 18 Injection), , http://www.fda.gov/downloads/AdvisoryCommittees/ CommitteesMeetingMaterials/Drugs/ PeripheralandCentralNervousSystemDrugsAdvisoryCommittee/UCM240265.pdf, Food and Drug Administration
Fleisher, A.S., Chen, K., Quiroz, Y.T., Jakimovich, L.J., Gomez, M.G., Langois, C.M., Florbetapir PET analysis of amyloid-ß deposition in the presenilin 1 E280A autosomal dominant Alzheimer's disease kindred: A cross-sectional study (2012) Lancet Neurol, 11, pp. 1057-1065. , 23137949 10.1016/S1474-4422(12)70227-2 1:CAS:528:DC%2BC38Xhs12gt7%2FO
Villemagne, V.L., Pike, K.E., Chételat, G., Ellis, K.A., Mulligan, R.S., Bourgeat, P., Longitudinal assessment of Aß and cognition in aging and Alzheimer disease (2011) Ann Neurol, 69, pp. 181-192. , 21280088 10.1002/ana.22248 1:CAS:528:DC%2BC3MXisVCisLs%3D
Ossenkoppele, R., Prins, N.D., Pijnenburg, Y.A., Lemstra, A.W., Van Der Flier, W.M., Adriaanse, S.F., Impact of molecular imaging on the diagnostic process in a memory clinic (2012) Alzheimers Dement, , 10.1016/j.jalz.2012.07.003 23164552
Grundman, M., Pontecorvo, M.J., Salloway, S.P., Doraiswamy, P.M., Fleisher, A.S., Sadowsky, C.H., Potential impact of amyloid imaging on diagnosis and intended management in patients with progressive cognitive decline (2013) Alzheimer Dis Assoc Disord, 27, pp. 4-15. , 23203162 10.1097/WAD.0b013e318279d02a 1:CAS:528:DC%2BC3sXis12rsLk%3D
Johnson, K. A., Minoshima, S., Bohnen, N. I., Donohoe, K. J., Foster, N. L., Herscovitch, P., Appropriate use criteria for amyloid PET: A report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's Association (2013) J Nucl Med, 54, pp. 476-490. , 23359661 10. 2967/jnumed. 113. 120618 1: CAS: 528: DC%2BC3sXltV2ks7g%3
Klunk, W. E., Engler, H., Nordberg, A., Wang, Y., Blomqvist, G., Holt, D. P., Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B (2004) Ann Neurol, 55, pp. 306-319. , 14991808 10. 1002/ana. 20009 1: CAS: 528: DC%2BD2cXisFKntb8%3D
Kemppainen, N. M., Aalto, S., Wilson, I. A., N gren, K., Helin, S., Br ck, A., Voxel-based analysis of PET amyloid ligand [11C] PIB uptake in Alzheimer disease (2006) Neurology, 67, pp. 1575-1580. , 16971697 10. 1212/01. wnl. 0000240117. 55680. 0a 1: STN: 280: DC%2BD28nmslagsQ%3D%3D
Gomperts, S. N., Rentz, D. M., Moran, E., Becker, J. A., Locascio, J. J., Klunk, W. E., Imaging amyloid deposition in Lewy body diseases (2008) Neurology, 71, pp. 903-910. , 18794492 10. 1212/01. wnl. 0000326146. 60732. d6 1: STN: 280: DC%2BD1cngs1amtw%3D%3D
Ch telat, G., Villemagne, V. L., Bourgeat, P., Pike, K. E., Jones, G., Ames, D., Relationship between atrophy and beta-amyloid deposition in Alzheimer disease (2010) Ann Neurol, 67, pp. 317-324. , 20373343
Santillo, A. F., Gambini, J. P., Lannfelt, L., L ngstr m, B., Ulla-Marja, L., Kilander, L., In vivo imaging of astrocytosis in Alzheimer's disease: An 11C-L-deuteriodeprenyl and PIB PET study (2011) Eur J Nucl Med Mol Imaging, 38, pp. 2202-2208. , 21853308 10. 1007/s00259-011-1895-9
Bacskai, B. J., Frosch, M. P., Freeman, S. H., Raymond, S. B., Augustinack, J. C., Johnson, K. A., Molecular imaging with Pittsburgh Compound B confirmed at autopsy: A case report (2007) Arch Neurol, 64, pp. 431-434. , 17353389 10. 1001/archneur. 64. 3. 431
Ikonomovic, M. D., Klunk, W. E., Abrahamson, E. E., Mathis, C. A., Price, J. C., Tsopelas, N. D., Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease (2008) Brain, 131, pp. 1630-1645. , 18339640 10. 1093/brain/awn016
Ikonomovic, M. D., Abrahamson, E. E., Price, J. C., Hamilton, R. L., Mathis, C. A., Paljug, W. R., Early AD pathology in a [C-11] PiB-negative case: A PiB-amyloid imaging, biochemical, and immunohistochemical study (2012) Acta Neuropathol., 123, pp. 433-447. , 22271153 10. 1007/s00401-012-0943-2 1: CAS: 528: DC%2BC38Xisl2ktbk%3D
Rowe, C. C., Ackerman, U., Browne, W., Mulligan, R., Pike, K. L., O'Keefe, G., Imaging of amyloid in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: Proof of mechanism (2008) Lancet Neurol, 7, pp. 129-135. , 18191617 10. 1016/S1474-4422 (08) 70001-2 1: CAS: 528: DC%2BD1cXis1WmsLw%3D
Wong, D. F., Rosenberg, P. B., Zhou, Y., Kumar, A., Raymont, V., Ravert, H. T., In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18F-AV-45 (florbetapir F 18) (2010) J Nucl Med, 51, pp. 913-920. , 20501908 10. 2967/jnumed. 109. 069088 1: CAS: 528: DC%2BC3cXosl2ksb4%3D
Clark, C. M., Schneider, J. A., Bedell, B. J., Beach, T. G., Bilker, W. B., Mintun, M. A., Use of florbetapir-PET for imaging beta-amyloid pathology (2011) JAMA, 305, pp. 275-283. , 21245183 10. 1001/jama. 2010. 2008 1: CAS: 528: DC%2BC3MXhtVGrurw%3D
Csel nyi, Z., J nhagen, M. E., Forsberg, A., Halldin, C., Julin, P., Schou, M., Clinical validation of 18F-AZD4694, an amyloid- -specific PET radioligand (2012) J Nucl Med, 53, pp. 415-424. , 22323782 10. 2967/jnumed. 111. 094029
Clark, C. M., Pontecorvo, M. J., Beach, T. G., Bedell, B. J., Coleman, R. E., Doraiswamy, P. M., Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid- plaques: A prospective cohort study (2012) Lancet Neurol, 11, pp. 669-678. , 22749065 10. 1016/S1474-4422 (12) 70142-4 1: CAS: 528: DC%2BC38XhtV2gtb3E
Rinne, J. O., Wong, D. F., Wolk, D. A., Leinonen, V., Arnold, S. E., Buckley, C., [18F] Flutemetamol PET imaging and cortical biopsy histopathology for fibrillar amyloid detection in living subjects with normal pressure hydrocephalus: Pooled analysis of four studies (2012) Acta Neuropathol, 124, pp. 833-845. , 23053137 10. 1007/s00401-012-1051-z 1: CAS: 528: DC%2BC38XhslKls7zI
Morris, J. C., Price, J. L., Pathologic correlates of nondemented aging, mild cognitive impairment, and early-stage Alzheimer's disease (2001) J Mol Neurosci, 17, pp. 101-118. , 11816784 10. 1385/JMN: 17: 2: 101 1: CAS: 528: DC%2BD3MXosVKitrg%3D
Kapucu, O. L., Nobili, F., Varrone, A., Booij, J., Vander Borght, T., N gren, K., EANM procedure guideline for brain perfusion SPECT using 99mTc-labelled radiopharmaceuticals, version 2 (2009) Eur J Nucl Med Mol Imaging, 36, pp. 2093-2102. , 19838703 10. 1007/s00259-009-1266-y 1: CAS: 528: DC%2BD1MXhsVCisb3L
Patel, M. R., Spertus, J. A., Brindis, R. G., Hendel, R. C., Douglas, P. S., Peterson, E. D., ACCF proposed method for evaluating the appropriateness of cardiovascular imaging (2005) J Am Coll Cardiol, 46, pp. 1606-1613. , 16226195 10. 1016/j. jacc. 2005. 08. 030
Fleisher, A. S., Chen, K., Quiroz, Y. T., Jakimovich, L. J., Gomez, M. G., Langois, C. M., Florbetapir PET analysis of amyloid- deposition in the presenilin 1 E280A autosomal dominant Alzheimer's disease kindred: A cross-sectional study (2012) Lancet Neurol, 11, pp. 1057-1065. , 23137949 10. 1016/S1474-4422 (12) 70227-2 1: CAS: 528: DC%2BC38Xhs12gt7%2FO
Villemagne, V. L., Pike, K. E., Ch telat, G., Ellis, K. A., Mulligan, R. S., Bourgeat, P., Longitudinal assessment of A and cognition in aging and Alzheimer disease (2011) Ann Neurol, 69, pp. 181-192. , 21280088 10. 1002/ana. 22248 1: CAS: 528: DC%2BC3MXisVCisLs%3D
Ch telat, G., Alzheimer disease: A -independent processes-rethinking preclinical AD (2013) Nat Rev Neurol, , 10. 1038/nrneurol. 2013. 21
Appropriate use criteria for amyloid PET imaging cannot replace guidelines: on behalf of the European Association of Nuclear Medicine
Not available. Non disponibile.
Appropriate use criteria for amyloid PET imaging cannot replace guidelines: on behalf of the European Association of Nuclear Medicine
Kim YH, Shin SW, Pellicano R, Fagoonee S, Choi IJ, Kim YI, Park B, Choi JM, Kim SG, Choi J, Park JY, Oh S, Yang HJ, Lim JH, Im JP, Kim JS, Jung HC, Ponzetto A, Figura N, Malfertheiner P, Choi IJ, Kook MC, Kim YI, Cho SJ, Lee JY, Kim CG, Park B, Nam BH, Bae SE, Choi KD, Choe J, Kim SO, Na HK, Choi JY, Ahn JY, Jung KW, Lee J, Kim DH, Chang HS, Song HJ, Lee GH, Jung HY, Seta T, Takahashi Y, Noguchi Y, Shikata S, Sakai T, Sakai K, Yamashita Y, Nakayama T, Leja M, Park JY, Murillo R, Liepniece-karele I, Isajevs S, Kikuste I, Rudzite D, Krike P, Parshutin S, Polaka I, Kirsners A, Santare D, Folkmanis V, Daugule I, Plummer M, Herrero R, Tsukamoto T, Nakagawa M, Kiriyama Y, Toyoda T, Cao X, Corral JE, Mera R, Dye CW, Morgan DR, Lee YC, Lin JT, Garcia Martin R, Matia Cubillo A, Lee SH, Park JM, Han YM, Ko WJ, Hahm KB, Leontiadis GI, Ford AC, Ichinose M, Sugano K, Jeong M, Park JM, Han YM, Park KY, Lee DH, Yoo JH, Cho JY, Hahm KB, Bang CS, Baik GH, Shin IS, Kim JB, Suk KT, Yoon JH, Kim YS, Kim DJ * Helicobacter pylori Eradication for Prevention of Metachronous Recurrence after Endoscopic Resection of Early Gastric Cancer(207 visite) N Engl J Med (ISSN: 0028-4793, 0028-4793linking, 1533-4406electronic), 2015 Jun; 30642104201566393291: 749-756. Impact Factor:59.558 DettagliEsporta in BibTeXEsporta in EndNote
Testino G, Leone S, Fagoonee S, Del Bas JM, Rodriguez B, Puiggros F, Marine S, Rodriguez MA, Morina D, Armengol L, Caimari A, Arola L, Cimini FA, Barchetta I, Carotti S, Bertoccini L, Baroni MG, Vespasiani-gentilucci U, Cavallo MG, Morini S, Nelson JE, Roth CL, Wilson LA, Yates KP, Aouizerat B, Morgan-stevenson V, Whalen E, Hoofnagle A, Mason M, Gersuk V, Yeh MM, Kowdley KV, Lee SM, Jun DW, Cho YK, Jang KS, Kucukazman M, Ata N, Dal K, Yeniova AO, Kefeli A, Basyigit S, Aktas B, Akin KO, Agladioglu K, Ure OS, Topal F, Nazligul Y, Beyan E, Ertugrul DT, Catena C, Cosma C, Camozzi V, Plebani M, Ermani M, Sechi LA, Fallo F, Goto Y, Ray MB, Mendenhall CL, French SW, Gartside PS Serum vitamin A deficiency and increased intrahepatic expression of cytokeratin antigen in alcoholic liver disease(423 visite) Hepatology (ISSN: 1827-1669electronic, 0026-4806linking), 1988 Sep; 83120693611123109(5): 1019-1026. Impact Factor:0.913 DettagliEsporta in BibTeXEsporta in EndNote
419 Records (406 escludendo Abstract e Conferenze). Impact factor totale: 1656.274 (1604.494 escludendo Abstract e Conferenze). Impact factor a 5 anni totale: 1603.59 (1544.548 escludendo Abstract e Conferenze).
Last modified by Ultima modifica di Marco Comerci on in data Sunday 12 July 2020, 13:14:53 433 views visite. Last view on Ultima visita in data Monday 18 January 2021, 21:38:07